# Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

> **NCT07080242** · PHASE1 · RECRUITING · sponsor: **SystImmune Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Small Cell Lung Cancer Metastatic or Locally Advanced
- Neuroendocrine Cancer
- Metastatic or Locally Advanced Neuroendocrine Prostate Cancer
- Metastatic or Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Metastatic or Locally Advanced Merkel Cell Carcinoma
- Locally Advanced or Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
- Metastatic or Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
- Poorly Differentiated and/or High Grade Neuroendocrine Neoplasms With Evidence of DLL3 Expression

## Interventions

- **DRUG:** BL-M14D1

## Key facts

- **NCT ID:** NCT07080242
- **Lead sponsor:** SystImmune Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07080242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07080242, "Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07080242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*